

## PUBLICATIONS

### THESES

#### **M.D.:**

Prophylactic use of chemotherapy in patients with Molar Pregnancy-10 years experience.  
Supervisor: Prof. M.R. Peizer.

#### **Ph.D.:**

Mechanisms of Oral Tolerance to Myelin Basic Protein and its Fragments in Experimental Autoimmune Encephalomyelitis.

Supervisors: Prof. O. Abramsky, The Hebrew University of Jerusalem and Prof. H.L. Weiner, Harvard Medical School, Boston.

### REFEREED PAPERS IN PROFESSIONAL JOURNALS

#### **A. Basic Research and Hypothesis-driven**

1. **Miller A.**, Harel D., Laor A., and Lahat N. Cimetidine as an immunomodulator in the treatment of Herpes-Zoster. *J. Neuroimmunol.* 22: 69-76, 1989.
2. Lider O., **Miller A.**, Miron S, Hershkoviz R., Weiner H.L., Zhang X., and Heber-Katz E. Non encephalitogenic CD4<sup>-</sup>CD8<sup>-</sup> V $\alpha$ 2V $\beta$  8.2<sup>+</sup> anti-Myelin Basic Protein rat T lymphocytes inhibit disease induction. *J. Immunol.* 147: 1208-1213, 1991.
3. **Miller A.**, Lider O., and Weiner L.H. Antigen driven bystander suppression after oral administration of antigens. *J. Exp. Med.* 174: 791-798, 1991. [I.F.=13.2]
4. Hershkoviz R., Miron S. , ICohen .R., **Miller A.**, and Lider . O. T lymphocytes adhesion to the fibronectin and laminin components of the extracellular matrix is regulated by the CD4 molecule. *Eur. J. Immunol.* 22: 7-13, 1992.
5. **Miller A.**, Lider O., Roberts A.B., Sporn B.M., and Weiner H.L. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of TGF- $\beta$  after antigen-specific triggering. *Proc. Natl. Acad. Sci. USA*, 89: 421-425, 1992. [I.F.=9.7].
6. **Miller A.**, Lider O., Al-Sabbagh A., and Weiner . H.L. Suppression of Experimental Autoimmune Encephalomyelitis by oral administration of Myelin Basic Protein. V. Hierarchy of suppression elicited by Myelin Basic Protein from different species. *J. Neuroimmunol.* 39: 243-250, 1992.
7. Hershkoviz R., Cahalon L. , Gilat D., Miron S. , **Miller A.**, and Lider . O. Physically damaged Extracellular Matrix induces TNF $\alpha$  secretion by interacting resting CD4<sup>+</sup> T cells and macrophages. *Scand. J. Immunol.* 37: 111-115, 1993.
8. Hershkoviz R., Alon R., Mekori Y.A., Gilat D., **Miller A.**, and Lider O. Heat-stress of CD4<sup>+</sup> T lymphocytes: Diverse modulation of adhesiveness to Extracellular Matrix

glycoproteins, Proliferative responses and cytokine production. *Immunol.*, 79: 241-S 247, 1993.

9. **Miller A.**, Zhang Z.J., Sobel R.A., Al-Sabbagh , A. and Weiner H.L. Suppression of Experimental Autoimmune Encephalomyelitis by oral administration of Myelin Basic Protein. VI. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization. *J. Neuroimmunol.*, 46: 73-82, 1993.

10. Lahat N., **Miller A**, Shtiller R. , and Touby E.. Differential effects of prolactin upon activation and differentiation of human B lymphocytes. *J. Neuroimmunol.* 47: 35-40, 1993.

11. **Miller A.**, Al-Sabbagh A. , Santos L.M.B. , Prabhu Das M., and Weiner . H.L. Epitopes of Myelin Basic Protein that trigger TGF- $\beta$  release following oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. *J. Immunology.* 151: 7307-7312, 1993.

12. Al-Sabbagh A., **Miller A**, Santos L.M.B. and Weiner H.L. Antigen driven tissue-specific suppression following oral tolerance: Orally administered Myelin Basic Protein suppresses PLP induced Experimental Autoimmune Encephalomyelitis in the SJL mouse. *European J. Immunology.* 24: 2104-2109, 1994.

13. **Miller A.**, Lider O. , Abramsky O., and Weiner H.L. Orally administered Myelin Basic Protein in neonates primes for immune responses and enhances Experimental Autoimmune Encephalomyelitis in adult animals. *European J. Immunology.* 24: 1026-1032, 1994.

14. Sorkine P., Setton A. , Halpern P., **Miller A**, Rudick V. , Marmor S., Klausner J.M., and Goldman G. Soluble TNF receptors reduce bowel ischemia-induced lung permeability and neutrophils sequestration. *Critical Care Med.* 23: 1377-1381, 1995.

15. **Miller A.**, Lanir N., Shapiro S., Revel M. , Honigman S., Kinarty A. and Lahat N. Immunoregulatory effects of interferon-  $\beta$  and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis. *J. Neuroimmunol.* 64: 151-161, 1996.

16. Barone FC, Arvin B., White R.F., **Miller A**, Webb C.L., Willette R.N., Lysk P.G. and Feuerstein G.Z. Tumor necrosis factor-  $\beta$ : A mediator of focal ischemic brain injury. *Stroke.* 28: 1233-1244, 1997.

17. **Miller A.**, Shapiro S. , Kinarty A., Gershtein R., Rawashdeh H., Honigman S., and Lahat N. Treatment of Multiple Sclerosis with Copolymer-1: Implicating Mechanisms of Th1 to Th2/Th3 Immune-Deviation. *J. Neuroimmunol.* 92: 113-121, 1998.

18. Shapiro S, Lahat N, Kinarty A, **Miller A**. Modulation of the co-stimulatory molecules B7-1, B7-2 & CD40 on monocytes by interferon-beta-1a (Rebif ) suggests Th1 to Th2 immune-deviation. *European Cytokine Network* 9: 529, 1998.

19. **Miller A.**, Kraiem Z. , Sobel E., Lider O., and Lahat N. Modulation of HLA and ICAM-1 expression in normal and neoplastic human thyroid cells by cytokines in the context of extracellular matrix. *Thyroid*. 11: 945-50, 2000.
20. Galboiz Y., Shapiro S., Lahat N., Rawashdeh H., and **Miller A.** Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) as markers of disease subtype and response to interferon-  $\beta$  therapy in relapsing and secondary progressive multiple sclerosis patients. *Ann. Neurol*. 50: 443-451, 2001. [I.F.=11.2].
21. Ben-Yosef Y., Lahat N., Shapiro S., Bitterman H., and **Miller A.** Regulation of Endothelial Matrix Metalloproteinase (MMP)-2 by Hypoxia/Reoxygenation. *Circulation Research* 90: 784-791, 2002. [I.F.= 11.8]
22. Galboiz Y., Shapiro S. , Lahat , N. and **Miller A.** Modulation of Monocytes Matrix Metalloproteinase (MMP)-2, MT1-MMP and TIMP-2 by Interferon-  $\gamma$  and - $\beta$  Implications to Multiple Sclerosis. *J. Neuroimmunol*. 131: 191-200, 2002.
23. Lahat N, Shapiro S., From P. , Kristal-Boneh E. , Inspector M., and **Miller A.** Inorganic Lead enhances cytokine-induced elevation of Matrix Metalloproteinase (MMP)-9 expression in glial cells. *J. Neuroimmunol*. 132: 123-128, 2002.
24. Abraham M., Shapiro S. , Lahat N. and **Miller A.** The role of IL-18 and IL-12 in the modulation of Matrix Metalloproteinases (MMPs) and their Tissue Inhibitors (TIMPs) in monocytic cells. *International Immunology*.14: 1449-1457, 2002.
25. Shapiro S., **Miller A.** \*, Lahat N. , Sobel E. , Lerner A.\* Expression of Matrix Metalloproteinases (MMPs), sICAM-1 and IL-8 in CSF from Children with Meningitis. *J. Neurol. Sci*. 206: 43-48, 2003. \*Equally contributing authors.
26. Shapiro S., Galboiz Y., Lahat N., Kinarty K., and **Miller A.** The 'Immunological-Synapse' at its APC side in Relapsing and Secondary-Progressive Multiple Sclerosis: Modulation by Interferon- $\beta$ . *J. Neuroimmunology* 144:116-124, 2003.
27. Birnboim S. and **Miller A.** Cognitive strategies application of multiple sclerosis patients. *Multiple Sclerosis Journal* 10: 67-73, 2004 [I.F = 4.2 ].
28. Grossman I., Avidan N. , Singer C. , Paperna T., Lancet D., Beckmann J. S. , and **Miller A.** Genomic Profiling of Inter-Population Diversity Guides Prioritization of Candidate-Genes for Autoimmunity. *Genes and Immunity* 5: 493-504, 2004 [I.F = 4.367 ].
29. Birnboim S. and **Miller A.** Cognitive rehabilitation for Multiple Sclerosis patients with executive dysfunction. *Journal of Cognitive Rehabilitation*. 22:11-18, 2004.
30. **Miller A.** and Dishon S. Health-Related Quality of Life in Multiple Sclerosis: Psychometric Analysis of Inventories. *Multiple Sclerosis Journal*. 11: 450-458, 2005 [I.F = 4.2 ].

31. Yahav R, J. Vosburgh J, and **Miller A**. Emotional responses of children and adolescents to parents with multiple sclerosis. *Multiple Sclerosis Journal* 11:464-468, 2005 [I.F = 4.2 ]..
32. Abraham M., Shapiro S., Karni A., Weiner H.L., and **Miller A**. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. *J Neuroimmunol.* 163:157-164, 2005 [I.F = 2.9 ].
33. Inspector M., Aharon- Perez J., Glass-Marmor L., and **Miller A**. Matrix Metalloproteinase (MMP)-9, its Tissue Inhibitor (TIMP)-1 and CRP in Alzheimer's Disease. *European Neurology*, 53:155-157, 2005.
34. Azoulay D., Vachapova V. , Shihman B., **Miller A**, Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate. *J Neuroimmunology.* 167: 215-218, 2005 [I.F = 2.9 ].
35. Ben-Yosef Y. , **Miller A** \*, Shapiro S. , Lahat N.\*. Hypoxia of endothelial cells leads to MMP-2 dependent survival and death. *Am J Physiol - Cell Physiol.* 289: 1321-1331, 2005.\*Equally contributing authors [I.F = 4.01 ].
36. **Miller A**. and Dishon S. Health-Related Quality of Life in Multiple Sclerosis: The impact of disability, gender and employment status. *Quality of Life Research.* 15: 259-271, 2006 [I.F = 1.95 ].
37. Baram Y., and **Miller A**. Virtual Reality Cues for Improvement of Gait in Patients with Multiple Sclerosis. *Neurology.* 66;178-181, 2006 [I.F = 8.17 ].
38. Alter M., Kahana E. , Zilber N., **Miller A**. Multiple Sclerosis frequency in Israel's diverse populations. *Neurology.* 66:1061-1066, 2006 [I.F = 8.17 ].
39. Schwarz M, Spector L. , Gortler M., Weishaus O., Glass-Marmor L., Karni A., Dotan N., **Miller A**. Serum Anti-Glc( $\alpha$ 1,4)Glc( $\alpha$ ) Antibodies as a Biomarker for Relapsing Remitting Multiple Sclerosis. *J Neurol. Sci.* 244(1-2):59-68, 2006 [I.F = 2.16 ].
40. Ben-Hur T., Ben-Yosef Y. , Mizrachi-Kol R. , Ben-Menachem O., **Miller A**. Cytokine - mediated modulation of MMPs and TIMPs in multi-potential neural precursor cells. *J Neuroimmunology.* 175: 12-18, 2006 [I.F = 2.9 ].
41. Panitch H.S., Thisted R.A., Smith R.A., Wynn D.R., Wymer J. P., Achiron , A. Vollmer T.L., Mandler R.N., Dietrich D.W., Fletcher M., Pope L.E., Berg J.E. and **Miller A**. Randomized Trial of Dextromethorphan/Quinidine for Pseudobulbar Affect in Multiple Sclerosis. *Ann. Neurol.* 59(5):780-7, 2006 [ I.F. =10.71 ].
42. Ochi H., Abraham M. , Ishikawa H., Frenkel D., Yang K., Basso A., Wu H., Chen M-L. , Gandhi R., **Miller A**, R. Maron. H.L. Weiner. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4(+)/CD25(-) LAP(+) T cells. *Nature Medicine.* 12, 627 - 635, 2006 [I.F = 27.1 ].

43. Melamed D., Messika O., Glass-Marmor L., and **Miller A.** Modulation of Matrix-Metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis. *International Immunology*. 18:1355-62, 2006 [I.F = 3.3].
44. Yahav R., Vosburgh J. and **Miller A.** Separation-individuation processes of adolescent children of parents with Multiple Sclerosis. *Multiple Sclerosis Journal* 13: 87-94. 2007[I.F = 4.2].
45. Gruenwald I., Vardi Y., Gartman I., Juven E. , Sprecher E., Yarnitsky D. and **Miller A.** Sexual dysfunction in females with Multiple Sclerosis: quantitative sensory testing. *Multiple Sclerosis Journal* 13:95-105, 2007[I.F = 4.2]
46. Baram Y, and **Miller A.** Auditory Feedback Control for Improvement of Gait in Patients with Multiple Sclerosis. *J. Neurol. Sci.* 15; 254: 90-4, 2007 [I.F = 2.16].
47. Glass-Marmor L., Paperna T. , Ben-Yosef Y., and **Miller A.** Chronotherapy using Corticosteroids for Multiple Sclerosis Relapses. *Journal of Neurology, Neurosurgery & Psychiatry* 78(8):886-8, 2007[I.F = 4.78].
48. Grossman I., Avidan N. , Singer C., Goldstaub D., Hayardeny L., Eyal E., Ben-Asher E., Paperna T., Pe'er I., Lancet D., Beckmann JB. and **Miller A.** Pharmacogenetics of Glatiramer Acetate therapy for Multiple Sclerosis reveals drug-response markers. *Pharmacogenetics and Genomics*. 17(8):657-666, 2007[I.F = 3.865].
49. Abraham M., Karni A., Dembinsky A., **Miller A.**, Gadhi R., Anderson D., H.L. Weiner. In vitro induction of regulatory T cells by anti-CD3 antibody in humans. *J. Autoimmunity*. 30, 21-28, 2008 [I.F = 8.136].
50. Golan D., Somer E., Dishon S. , Cuzin-Disegni L. and **Miller A.** Impact of exposure to war stress on exacerbations of Multiple Sclerosis. *Annals of Neurology* 64(2):143-8, 2008.  
[I.F = 10.74].
51. Haiman G., Pratt H. and **Miller A.** Brain responses to verbal stimuli among Multiple Sclerosis patients with Pseudobulbar Affect. *J Neurol. Sci.* 271. 137-147, 2008 [I.F = 2.16].
52. Neter E., Litvak A., and **Miller A.** Goal disengagement and goal reengagement among Multiple Sclerosis patients: Relationship to wellbeing and illness representation. *Psychology & Health* 24(2), 175-186, 2009.
53. Glass-Marmor L., Paperna T., Galboiz Y., **Miller A.** Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses. *J Neuroimmunology* 210: 124-127, 2009 [I.F = 2.9].
54. Haiman G., Pratt H. and **Miller A.** Effects of dextromethorphan/quinidine on auditory event related potentials in Multiple Sclerosis patients with Pseudobulbar Affect. *Journal of Clinical Psychopharmacology*. 29(5):444-52, 2009 [I.F = 5.09].

55. Shatil E., Metzger A. , Horvitz O. and **Miller A.** Home-based personalized cognitive training in MS patients: A study of adherence and cognitive performance. *NeuroRehabilitation* 26(2):143-53. 2010.[I.F = 1.9 ].
56. Mizrachi K., Feferman R. A.T. , Kela-Madar N., Mandel I., Paperna T. , **Miller A.**, Ben-Nun A., Berrih-Aknin S., Souroujon M.C., Fuchs S.  
INVOLVEMENT OF PHOSPHODIESTERASES IN AUTOIMMUNE DISEASES. *J NEURO-IMMUNOLOGY* 220, (1): 43-51, 2010 [I.F = 2.9 ].
57. Baram Y. and **Miller A.** Glide-symmetric locomotion reinforcement in patients with multiple sclerosis by visual feedback. *Disability & Rehabilitation Assist Technol.* 5(5):323-6, 2010. [I.F = 1.489 ].
58. Somer E., Golan D. , Dishon S. , Cuzin-Disegni L. , Lavi I., and **Miller A.** Multiple Sclerosis patients in a war zone: Coping strategies associated with reduced risk for relapse. *Multiple Sclerosis Journal* 16(4):463-71, 2010. [I.F = 4.2 ].
59. Benedek G., Paperna T. , Avidan N.; Lejbkowicz I., Oksenberg J. R., Wang J. , Brautbar C. , Israel S., and **Miller A.** Opposing effects of the *HLA-DRB1\*0301-DQB1\*0201* haplotype on the risk of developing multiple sclerosis in diverse Arab populations in Israel. *Genes & Immunity* 11, 423–431, 2010.  
[I.F = 4.367 ].
60. Saaroni H., Sigal A. , Lejbkowicz I., and **Miller A.** Mediterranean climate conditions and exacerbations of Multiple Sclerosis. *Neuroepidemiology* 35:142-151, 2010.  
[I.F = 2.48 ].
61. Lejbkowicz I., Paperna T., Stein N. , Dishon S. and **Miller A.** Internet usage by patients with multiple sclerosis: Implications to participatory medicine and personalized healthcare. *Multiple Sclerosis International*. Volume 2010, Article ID 640749, 7 pages, 2010.
62. Staun-Ram E., **Miller A.** Cathepsins (S and B) and their Inhibitor Cystatin C in immune Cells: Modulation by Interferon- $\gamma$  and role played in cell migration. *J. Neuroimmunology* 232:200-206, 2011 [I.F = 2.9 ].
63. Haves-Zbufof D., Paperna T., Gour-Lavie A., Mandel I. , Glass-Marmor L. , **Miller A.** Cathepsins and their endogenous inhibitors Cystatins: Expression and Modulation in Multiple Sclerosis. *Journal of Cellular and Molecular Medicine (J of Translational Medicine)* 15: 2421-9, 2011 [I.F = 4.6 ].
64. Ionescu R., Broza Y. , Brande H. , Glazer D. , Zilberman Y., Feng X. , Glass-Marmor L. , Müllen K., **Miller A.**, Haick H. Detection of Multiple Sclerosis from Exhaled Breath using Bilayers of Polycyclic Aromatic Hydrocarbons and Single-Wall Carbon Nanotubes. *ACS Chemical Neuroscience*. 2(12); 687-693, 2011.
65. Zissman K., Lejbkowicz I. , **Miller A.** Telemedicine for Multiple Sclerosis patients: Assessment Using Health Value Compass. *Multiple*

*Sclerosis Journal* 18(4):472-80, 2012 [I.F = 4.2 ].

66. Mandel I., Paperna T., Glass-Marmor L., Volkowich A. , Badarny S. , Schwartz I. , Vardi P. , Koren I. , **Miller A.** Tight Junction Proteins Expression and Modulation in Immune Cells and Multiple Sclerosis. *J of Cellular & Molecular Medicine (J of Translational Medicine)*. 16(4):765-75, 2012 [I.F = 4.6 ]

67. Melamud A., Golan D. , Luboshitzky R. , Lavi I., **Miller A.** Melatonin dysregulation, sleep disturbances and fatigue in Multiple Sclerosis. *J Neurol. Sci.* 314: 37-40, 2012.

68. Mandel I., Paperna T., **Miller A.** Aberrant expression of the apoptosis-related proteins BAK and MCL1 in T cells in Multiple Sclerosis. *J Neuroimmunology*. 244(1-2):51-6. 2012 [I.F = 2.9 ].

69. Mandel I., T. Paperna, A. Volkowich, M. Merhav, L. Glass-Marmor, **Miller A.** The ubiquitin-proteasome pathway regulates claudin 5 degradation. *J Cell Biochem*. 113: 2415-2423. 2012.

70. Toubi E., Nussbaum S. , Staun-Ram E., Snir A., Melamed D., Hayardeny L., **Miller A.** Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis. *J Neuroimmunology* 251(1-2):45-54. 2012. [I.F = 2.9 ].

71. Golan D., Halhal B., Glass-Marmor L., Staun-Ram E., Rozenberg O., Lavi I., Dishon S., Barak M., Ish-Shalom S., **Miller A.** Vitamin D supplementation for patients with Multiple Sclerosis treated with Interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. *BMC Neurology* . 2013 Jun 14;13(1):60. [Epub ahead of print]

72. Golan D., Halhal B., Glass-Marmor L., Staun-Ram E., Lavi I., Dishon S., Barak M., Ish-Shalom S., **Miller A.** The influence of Vitamin D on Melatonin status in patients with Multiple Sclerosis. *Brain, Behavior, and Immunity* . 32: 180-185. 2013. 2013 Aug;32:180-5. doi: 10.1016/j.bbi.2013.04.010. Epub 2013 May 7. [I.F= 4.72 ].

73. Tzunz N., Avidan N., Mandel I., Staun-Ram E., Paperna T. , Pinter R. Y. , **Miller A.** Interferon-Beta Induces Distinct Gene Expression Response Patterns in Human Monocytes versus T cells. *PlosONE* 8:e62366 1-17, 2013. PLoS ONE 8(4): e62366. doi:10.1371/journal.pone.0062366

74. Ben-Ami E., **Miller A.**, Berrih-Aknin S. T cells from autoimmune patients display reduced sensitivity to immunoregulation by Mesenchymal Stem Cells: Role of IL-2. *Autoimmune Review* (original article) . 13: 187-196. 2014. [I.F = 7.9].

75. Avidan N., Le Panse R., Harbo H., Bernasconi P., Poulas K., Ginzburg E., Cavalcante P., Colleoni L., Baggi F., Antozzi C., Truffault F., Horn-Saban S., Pöschel S., Zagoriti Z., Maniaol A., Lie BA., Bernard I., Saoudi A., Illes Z., Casasnovas Pons C., Melms A., Tzartos S., Willcox N., Kostera-Pruszczyk A., Tallaksen C., Mantegazza R., Berrih-Aknin S. \*, **Miller A.**<sup>1,18\*</sup>

VAV1 and BAFF, via NFkB pathway, are genetic risk factors for Myasthenia Gravis. *Annals of Clinical and Translational Neurology (ACTN)* 1(5), 329-339. 2014.

76. Khsheibun R. , Paperna T., Volkowich A., Lejbkowicz I., Avidan N., **Miller A.** Gene expression profiling of the response to interferon beta in EBV-transformed and primary B cells of patients with multiple sclerosis. *PLoS One* Jul 15;9(7):e102331, 2014.

77. Shimrat Mamrut, Nili Avidan, Elsebeth Staun-Ram, Elizabeta Ginzburg, Frederique Truffault, Sonia Berrih-Aknin, **Ariel Miller** Integrative analysis of methylome and transcriptome in human blood identifies extensive sex- and immune cell-specific differentially methylated regions *Epigenetics* 10(10):943-57, 2015. [IF: 4.78.]

78. Blumenfeld, S., Staun-Ram E., **Miller A.** Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis. *J. Autoimmunity*. 70: 40-51, 2016. [I.F.=8.41].

79. Morad K. Nakhleh, Haitham Amal, Raneen Jeries, Yoav Y. Broza, Manal Aboud, Alaa Gharra, Hodaya Ivgi, Salam Khatib, Shifaa Badarneh, Lior Har-Shai, Lea Glass-Marmor, Izabella Lejbkowicz, **Ariel Miller**, Samih Badarny, Raz Winer, John Finberg, Sylvia Cohen-Kaminsky, Frédéric Perros, David Montani, Barbara Girerd, Gilles Garcia, Gérald Simonneau, Farid Nakhoul, Shira Baram, Raed Salim, Marwan Hakim, Maayan Gruber, Ohad Ronen, Tal Marshak, Ilana Doweck, Ofer Nativ, Zaher Bahouth, Da-you Shi, Wei Zhang, Qingling Hua, Yue-yin Pan, Li Tao, Hu Liu, Amir Karban, Eduard Koifman, Tova Rainis, Roberts Skapars, Armands Sivins, Guntis Ancans, Inta Liepniece-Karele, Ilze Kikuste, Ieva Lasina, Ivars Tolmanis, Douglas Johnson, Stuart Z. Millstone, Jennifer Fulton, John W. Wells, Larry H. Wilf, Marc Humbert, Marcis Leja, Nir Peled, and Hossam Haick. Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules *ACS Nano*. 11:112-125, 2017 [ IF= 13.4].

80. Mamrut S., N. Avidan. Truffault, E. Staun-Ram, T. Sharshar, B. Eymard, M. Frenkian, J. Pitha, M. de Baets, L. Servais, S. Berrih-Aknin, **A. Miller.** Methylome and Transcriptome Profiling in Myasthenia Gravis Monozygotic Twins.



*J Autoimmunity* . 82: 62-73. 2017. [IF= 7.7 ]

81. Broza, Y.; Har-Shai, L.; Jeries, R.; Cancilla, J. ; Glass-Marmor, L.; Lejbkowitz, I.a; Torrecilla, J.; Yao, X. ; Feng, X.; Narita, A.; Müllen, K.; **Miller, A.**; Haick, H.

Exhaled Breath Markers for Non-Imaging and Non-Invasive Measures for Detection of Multiple Sclerosis" *ACS Chemical Neuroscience* (In press) [ IF= 3.88].

## **B. Clinical Research**

82. Bazak I., **Miller A**, and Uri N. Oculosympathetic paresis caused by foreign body perforation of pharyngeal wall. *Post. Grad. Med. J.* 9: 681-683, 1987.

83. Gadoth N., Melamed E., **Miller A**, Steiner I., Abramsky O. Intravenous immunoglobulin treatment in multiple sclerosis. *Neurology (letter)* 52: 214-215, 1999.

84. Tan I.L., Nijeholt C.J. L.a, Polman C.H., Ader H.J., Fbarkhof and the 95 line 146/147 study group. Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. *Multiple Sclerosis.* 6: 99-104, 2000.

85. Steinmetz D., Edelstein H., Dishon S. , Berkovits E., Almany A. And **Miller A**. Hospital-at-home as a solution for the treatment requirements of acute exacerbation in multiple sclerosis. *Harefuah, J. of Isr. Med. Ass.* 140: 6036-6, 2001.

86. Biermann L.D., Bohlega S. , Chofflon M.P.D., Gebeily S., Havrdova E. , Jakab G. , Karabudak R. , Selmaj K., **Miller A**. Treatment optimization in multiple sclerosis. *Eur. J. of Neurol.* 11:43–47, 2004 [IF= 3.765 ]..

87. Karussis D., Biermann L.D., Bohlega S. , Boiko A., Chofflon M., Fazekas F., Freedman M., Gebeily S., Gouider R., Havrdova E. , Jakab G. , Karabudak R. , **Miller A**. A recommended treatment algorithm in relapsing multiple sclerosis. *Eur J Neurol.* 13(1):61-71.2006. [IF= 3.765].

88. Har-Shai Y., Barak A., Taran A., Mayblum S. , Dunkelgrun M., **Miller A**. Facia lata support to eyelid and facial disfigurement in a syringomyelia patient. *Journal of Plastic, Reconstructive and Aesthetic Surgery.* 59: 888-889, 2006.

89. Goodin D.S., Biermann L.D., Bohlega S., Boiko A., Chofflon M., Gebeily S., Gouider R., Havrdova E., Jakab G., Karabudak R., Karussis D., **Miller A**, Pakdaman H., Selmaj K., Sharief M., Ms FT. Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. *Curr Med Res Opinion* 23: 2823-32, 2007. [IF= 2.65 ]

90. Siegel M., Paperna T., Lejbkowitz I., Petrou P., Shahein R., Karussis D, Dishon S., **Miller A**. Multiple Sclerosis in diverse populations: Characteristics

in diverse Arab ethnicities in Israel. *Multiple Sclerosis Journal*. 12:1737-44, 2012 [I.F.=4.2].

91. Golan D, Gross B, **Miller A**, Klil-Drori S, Lavi I, Shiller M, Honigman S, Almog R, Segol O. Cognitive function of patients with Crohn's disease is associated with intestinal disease activity  
*Inflammatory Bowel Diseases*. ;22(2):364-71. 2016.  
[IF: 4.46].

92 . Savin Z., Izabella Lejbkowicz I. , Glass-Marmor L., Lavi I., Rosenblum S., **Miller A**.  
Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the Manual Functions of Patients with Multiple Sclerosis.  
*J Neurol. Sci* 15;360:102-9, 2016.

### **C. REVIEW PAPERS**

93. **Miller A.**, Gross B., and Tourizkkite T.. Neurological complications of Herpes- Zoster infections, possible mechanisms. *Harefuah, J. of Isr. Med. Ass.* CVIII, 12: 598-601, 1985.

94. **Miller A.**, and Bazak I. Oculosympathetic paresis, Horner`s syndrome, clinical aspects. *Harefuah, J. of Isr. Med. Ass.* CXII, 9: 447-448, 1987.

95. **Miller A.**, and Harel D. The Blood Brain Barrier. Neurobiological and Neuroimmunological aspects. *Harefuah, J. of Isr. Med. Ass.* CXV, 7: 190-194, 1988.

96. **Miller A.**, and Harel D.I. The Blood brain barrier. Clinical applications. *Harefuah, J. of Isr. Med. Ass.* LXV, 9: 233-237, 1988.

97. **Miller A.**, Lider O., and Arnon R. Thymus, clonal deletion and suppressor systems in demyelinating diseases. *Harefuah, J. of Isr. Med. Ass.*120: 756-757, 1991.

98. **Miller A.**, Hafler D.A., and Weiner H.L. Immunotherapy in autoimmune diseases. In: Edit. I.R. Cohen & M. Weigert. *Current Opinion in Immunol.* 3, 936-940, 1991. [I.F.=5.7]

99. **Miller A.**, Hafler D.A. , and Weiner H.L. Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: Implications for immunotherapy of human autoimmune diseases. *FASEB J.*, 5: 2560-2566, 1991.

100. **Miller A.**, Weiner H.L. and Abramsky O. The Trimolecular Complex as a target for specific immunotherapy in Experimental Allergic Encephalomyelitis: Implications for Multiple Sclerosis and human autoimmune diseases.  
*Harefuah, J. of Isr. Med. Ass.* 123: 110-115, 1992.

101. Weiner H.L., Zang Z.J., Khoury S.J., **Miller A.**, Al-Sabbagh A. , Brod S., Lider O., Higgins P., Sobel R., and Hafler D.A. Antigen-driven peripheral tolerance Suppression of organ specific autoimmune diseases by oral administration of antigens, in *Antigen and Clonal-Specific Immunoregulation* , ed. Edelson, R.L., *New York. Acad.of Sciences, NY.* pp 227-232, 1992.
102. Weiner H.L., **Miller A**, Khoury S.J. , Zang Z.J. , Al-Sabbagh A., Brod S., Lider O., Higgins P., Sobel R., Matsui M. , Sayegh M., Carpenter C., Eisenbarth G., Nussenblatt R.B., and Hafler D.A. Suppression of organ-specific autoimmune diseases by oral administration of autoantigens. *Progress in Immunology . 8<sup>th</sup> International Congress of Immunology, Budapest, Hungary.* pp. 627-634, 1992.
103. **Miller A.**, and Abramsky O.. Neuroimmune Interactions and their Regulation. *Harefuah, J. of Isr. Med. Ass.* 124: 451-452, 1993.
104. Steinman L., **Miller A**, Bernard C.C.A., and Oxsenberg J.R.. The epigenetics of Multiple Sclerosis: Clues to etiology and a rationale for immune therapy. *Annual. Rev. Neurosci.* 17: 247-265, 1994. [I.F.=20.6]
105. Cahalon L., Herskoviz R., Gilat D., **Miller A**, Akiyama S.K., Yamada K.M., and Lider O. Functional interactions of fibronectin and TNF $\alpha$ : A paradigm of physiological linkage between cytokines and extracellular matrix. *Cell adhesion & Communication.* 2: 269-273, 1994.
106. Weiner H.L., Friedman A., **Miller A**, Khoury S.J., Al-Sabbagh A., Santos L., Ayegh M. , N ussenblutt R.B., Trenttham D.E., and Hafler D.A. Oral tolerance: Immunological mechanisms and treatment of murine and human organ specific autoimmune diseases by oral administration of autoantigens. Antigen-driven peripheral tolerance Suppression of organ specific autoimmune diseases by oral administration of antigens. *Annual. Rev. Immunol.* 12: 809-837, 1994.
107. **Miller A.** Demyelinating diseases and Multiple Sclerosis. In: *Clinical Neuroimmunology.* Abramsky O & Hartung H-P.(Eds). European Neurological Society (ENS)-Publishers, Munich, 44-51, 1995.
108. Weiner H.L., **Miller A**, Khoury S.J., Zang Z.J. , Al-Sabbagh A., Brod S.A. , Lider O., Higgins P., Sobel R., Matsui M., et al. Treatment of autoimmune diseases by oral tolerance to autoantigens. *Adv. Exp. Med. Biol.* 371B: 1217-23, 1995.
109. **Miller A.** Multiple sclerosis and demyelinating diseases of the central nervous system. In: *Clinical Neuroimmunology.* Abramsky O & Hartung H-P.(Eds.). European Neurological Society (ENS)-Publishers, Den Haag, 30-41, 1996.

110. **Miller A.**, Compston A. , and Martin R. Immune-Mediated Brain Injury and Repair: Mechanisms and Therapies. Conference review. *IMAJ*. 233-236. 2001.
111. Galboiz Y., Shapiro S., Lahat N., and **Miller A.** MMPs Involvement in Diseases of the Central Nervous System. *Harefuah, J. of Isr. Med. Ass.* 140: 329-333, 2001.
112. Freedman M.S., Blumhardt L.D., Brochet B., Comi G., Noseworthy J.H., Sandberg-Wollheim M., Soelberg-Sorensen P., and the Paris Working Group. International consensus statement on the use of disease-modifying agents in multiple sclerosis. *Multiple Sclerosis* 8: 19-23, 2002.
113. **Miller A.**, and Galboiz Y. Multiple Sclerosis: From basic Immunopathology to Immune -Intervention. *Clin. Neurol. Neurosurg.* 104: 172-6, 2002.
114. Galboiz Y., and **Miller A.** Immunological indicators of disease activity and prognosis in Multiple Sclerosis. *Current Opinion in Neurology.* 15: 233-237, 2002.
115. Karussis D., Brenner T., and **Miller A.** Neuroimmunology in Israel-2002: Proceedings of the 2nd Annual Meeting of the Israel Society of Neuroimmunology. *J. Neuroimmunol.* 131: 1-6, 2002.
116. Kirstein-Grossman I., Beckmann J.S. , Lancet D. and **Miller A.** Pharmacogenetic development of Personalized Medicine: Multiple Sclerosis treatment as a model. *Drugs, News & Perspectives.* 15: 558-567, 2002.  
<http://www.ncbi.nlm.nih.gov/pubmed/12677195?dopt=Abstract>
117. Grossman I., Paperna T., Beckmann J.S., Lancet D. and **Miller A.** Pharmacogenetics and Brain Diseases. *Neurology Update.* 11: 18-24, 2003.
118. **Miller A.**, Glass-Marmor L. , Abraham M., Grossman I., Shapiro S. and Galboiz Y. Bio-Markers of Disease Activity and Response to Therapy in Multiple Sclerosis. *Clin. Neurol. Neurosurg.* 106: 249-254, 2004 [ IF= 1.636 ].
119. **Miller A.**, Korem M., Almog R., Galboiz Y. Vitamin B12, Demyelination, Remyelination and Repair in Multiple Sclerosis. *J. Neurol. Sci.* 233/1-2: 93-97, 2005 [ IF= 2.167 ].
120. **Miller A.** Pseudobulbar affect in Multiple Sclerosis: Toward the Development of Innovative Therapeutic Strategies. *J Neurol Sci.* 245(1-2): 153-9, 2006 [ IF= 2.167 ].
121. Fontoura P., Steinman L. , **Miller A.** Emerging therapeutic targets in multiple sclerosis. *Current Opinion in Neurology.* 19:260-266, 2006 [ I.F. = 5.021].

122. **Miller A.**, Panitch H. Therapeutic use of Dextromethorphan: Key learnings from treatment of pseudobulbar affect. *J Neurol Sci.* 259: 67-73, 2007 [ I.F. = 2.167 ].
123. Golan D. & **Miller A.** Clinically Isolated Syndrome (CIS) suggestive of Multiple Sclerosis: Diagnosis, Prognosis and therapeutic approach. *Medicine /Neurology.* (Hebrew). 216-220, 2007.
124. **Miller A.**, N. Avidan. N. Tzunz, L. Glass-Marmor, I. Lejbkovicz, R. Pinter, T. Paperna. Translation towards 'Personalized Medicine' in Multiple Sclerosis. *J. Neurol. Sci.* 274: 68-75, 2008 [ I.F. = 2.167 ]. .
125. Ochi H., Abraham M., Ishikawa H., Frenkel D., Yang K., Basso A., Wu H., Chen M.L., Gandhi R., **Miller A.**, Maron R., Weiner HL. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. *J Neurol Sci.* 15;274(1-2):9-12, 2008 [ I.F. = 2.167 ].
126. **Miller A.**, Souroujon M., Aloisi F.. Translational Neuroimmunology: A joint Meeting of the Israel Society of Neuroimmunology and Associazione Italiana Neuroimmunologia - Conference review. *J. Neuroimmunol.* 216: 4-7, 2009 [ I.F. = 2.4 ].
127. Grossman I., **Miller A.** Multiple Sclerosis Pharmacogenetics: Personalized approach towards Tailored Therapeutics. *EPMA-J* 1:317-327, 2010.
128. Ben-Ami E., Berrih-Aknin S. , **Miller A.** Mesenchymal stem cells as an immunomodulatory therapeutic strategy for Autoimmune Diseases. *Autoimmune Reviews* 10: 410-5. 2011[ I.F. = 7.97 ].
127. **Miller A.**, Pratt H., Schiffer R.B. Pseudobulbar Affect: The Spectrum of Clinical Presentations, Etiologies, and Treatments. *Expert Review of Neurotherapeutics* 11(7):1077-88. 2011[ I.F. = 3.38 ].
130. Kappos L., Bates D., Edan G. , Eraksoy M., Garcia-Merino A., Grigoriadis N., Hartung H-P., Havrdová E., Hillert J. , Hohlfeld R. , Kremenchutzky M. , Lyon-Caen O. , **Miller A.**, Pozzilli C., Ravnborg M., Saida T., Sindic C., Vass K., Clifford D., Hauser S., Major E. O., O'Connor P., Weiner H., Clanet M., Gold R., Hirsch H., Radü E-W., Sørensen P S., King J. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. *Lancet Neurology.* (8):745-58, 2011. PMID:21777829 [PubMed - in process] [ I.F. = 21.65 ].
131. Lejbkovicz I., Caspi O., **Miller A.** Participatory Medicine and patient empowerment towards Personalized Healthcare in Multiple Sclerosis. *Expert Review of Neurotherapeutics.* (3):343-52, 2012. [I.F.=3.38].
132. Milo R. and **Miller A.** Revised Diagnostic Criteria of Multiple Sclerosis.

*Autoimmune Reviews*. (Invited Review). 13:518-524, 2014. [IF: 7.97].

133. Avidan N., Rozen Le Panse R., Berrih-Aknin S., **Miller A.**  
Genetic basis of Myasthenia Gravis - a Comprehensive Review.  
*J of Autoimmunity*\_52: 146-53. 2014. [IF: 8.145 ].

134. Golan D., Staun-Ram E., **Miller A.**  
Shifting paradigms in Multiple Sclerosis: from disease-specific, through population-specific towards patient-specific.  
*Current Opinion Neurology*. (Invited Review). 29: 354-361. 2016. [IF: 4.469].

135. Staun-Ram, E., **A. Miller.**  
Effector and Regulatory B cells in Multiple Sclerosis  
*Clinical Immunology* 2017 (In Press).

#### **D. BOOK CHAPTERS**

136. **Miller A.** & Honigman S. Therapeutic strategies in multiple sclerosis. In: Multiple sclerosis: Advances in the diagnosis and treatment. Abramsky O. and Ovadia H. (Eds.) Martin Dunitz Publishers. London, p.195-204, 1996.

137. Feuerstein G.Z. & **Miller A.** Vasoactive Mediators of Cerebrovascular Vessels. In: Primer on Cerebrovascular Diseases. Conner E. (Ed.) Academic Press, San Diego, p. 8-14, 1997.

138. **Miller A.**, Gross B., Rawashdeh H., Almog R., Gozlan O., Honigman S., & Gruener N. Changes in Serum and CSF Superoxide Dismutase (SOD) and Neuron Specific Enolase (NSE) in following acute cerebral ischemia. In: Advances in Critical Care Testing. List W.F., Muller M.M. & McQueen M.J. (Eds.) Springer, Berlin, p. 73-84, 1997.

139. Shapiro S., Lahat N., Kinarty A. , Gershtein R., Rawashdeh H., Honigman S. & **Miller A.** Suppression of disease activity in multiple sclerosis by Copolymer-1 (Copaxone) treatment is associated with downregulation of CD4+ T-cell activation. in: Korczyn A.D. (Ed.) Proceedings of the 4th Congress of the European Society for Clinical Neuropharmacology. Monduzzi Editore, Bologna, Italy, p. 131-137, 1997.

140. Lahat N., Shapiro S. , Inspector M., Reich R., Gershtein R. & **Miller A.** Matrix Metalloproteinases (MMPs) in astroglial cells. In: Progress in Alzheimer's and Parkinson's Diseases. A. Fisher, I. Hanin. and M. Yoshida (Eds.). Plenum Press, p. 149-157, 1998.

141. Weiner H.L. & **Miller A.** Oral Tolerance: Basic mechanisms and implications to immune-mediated neurological diseases. In: Immunotherapy in Neuroimmunology. J. Zhang, R. Hohlfeld, D. Hafler & A. Miller (Eds.). Martin Dunitz Publishers. London, p. 233-143, 1998.

142. **Miller A.**, Shapiro S. & Lahat N. Immunomodulation in multiple sclerosis and cytokine responses. In: *Frontiers in Multiple Sclerosis-II*. Kesselring, Siva and Thompson (Eds.) Martin Dunitz Publishers. London, p. 127-138, 1999.
143. Braker C., Shapiro S. , Lahat N., Honigman S., & **Miller A.** Matrix Metalloproteinases (MMPs) and IL-8 CSF-levels are correlated with Brain Edema following Cerebral Infarction. In: *Advances in Critical Care Testing 1999*. List W.F., Muller M.M., John A.St., (Eds.) Springer, Berlin, p. 103-104, 1999.
144. Lahat. N., **Miller A** & Rahat M. Significance and Regulation of the expression of MHC class-II molecules on autoimmune and neoplastic thyroid cells. In: *Cancer & Autoimmunity*. Shenfeld Y. & Gershwin E.M. (Ed.). Elsevier, Amsterdam, p. 317-335, 2000.
145. **Miller A.** and Zhang J. T Cell Vaccination and Antigen-Driven Immunotherapy for Multiple Sclerosis. In: *Multiple Sclerosis: Tissue destruction and Repair*. Kappos L. Johnson K, Kesselring J. Radu EW (Eds.). Martin Dunitz Publishers. London, p. 233-244, 2001.
146. **Miller A.**, Ben-Basat Y., Braker C., and Shapiro S. Modulation of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Hypoxia - Reperfusion injury and Stroke. In: *Inflammation & Stroke*. Giora Feuerstein (Ed.). Progress in Inflammation Research (PIR). Birkhauser Verlag AG, Basel, Switzerland, p. 275-285, 2001.
147. Ben-Yosef Y., Shapiro S., **Miller A**, Lahat N. Hypoxia simultaneously enhances Matrix Metalloproteinase-2 and apoptosis in endothelial cells. In: *Tumor Microenvironment: Progression, Therapy & Prevention*. Witz I.P. (Ed.) Monduzzi Editore, p. 145-152, 2002.
148. **Miller A.**, Shapiro S. , Lahat N. , and Galboiz Y. Matrix Metalloproteinases and their inhibitors in brain injury and repair. in: *Brain Disease: Therapeutic strategies and repair*. Abramsky O., Compston A., **Miller A.** & Said G. (Eds.) Martin Dunitz Publishers. London, p. 63-68, 2002.
149. Milo R., **Miller A.** Multiple Sclerosis. In: *Diagnostic criteria in Autoimmune Diseases*. Shoenfeld Y., Cervera R., Gershwin E.M. (Editors). The Human Press Inc. NJ. USA. p. 401-6, 2008.
150. **Miller A.**, Paperna T. , Caspi O., Lejbkowitz I. , Staun-Ram E. , Avidan N. Theranostics and Translation towards Personalized Medicine for Multiple Sclerosis. In: "Personalized Medicine, Healthcare and Integrative Neuroscience ". E. Gordon & S. H. Koslow, (Eds). Oxford University Press. p. 205-254. 2010
151. Paperna T., Staun-Ram E., Avidan N., Lejbkowitz I., **Miller A.** Personalized Medicine and Theranostics: Applications to Multiple Sclerosis.

In: Translational Neuroimmunology in Multiple Sclerosis: From Disease Mechanisms to Clinical Applications. Arnon R. and Miller A. (Eds.) Elsevier / Academic Press. San Diego, CA. p.429-454 , 2016.